Albany Molecular Research (AMRI) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
AMRI Announces First Quarter 2017 Results
May 9, 2017 7:30 AM EDTALBANY, N.Y., May 9, 2017 /PRNewswire/ --Â AMRI (NASDAQ: AMRI) today reported financial and operating results for the first quarter ended March 31, 2017 and provided an update to its outlook for 2017.
Highlights:
First quarter total revenue of $163.8 million, up 55% from 2016 First quarter basic and diluted EPS $(0.25); non-GAAP diluted EPS of $0.13 First quarter net loss of $(10.7) million; non-GAAP net income of $5.7 million First quarter adjusted EBITDA of $24.0 million, up 83% from 2016 Company confirms 2017 financial guidanceNon-GAAP net income, non-GAAP diluted EPS... More
